Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 15, 2025
Artios Pharma Announces Details of Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire
·
April 15, 2025
CAMBRIDGE, United Kingdom and NEW YORK, April 15, 2025 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today announced that the company’s abstract featuring clinical …
Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs
GlobeNewswire
·
April 15, 2025
New indications discovered by applying active machine learning and using samples from the company’s vast biobank of live-cell tumors specimens Builds upon Predictive’s biomarker discovery platform to select targeted patient cohorts to significantly de-risk …
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans
GlobeNewswire
·
April 15, 2025
Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s pipeline diversification beyond BNC210 US $15M milestone payment from Merck extends company’s cash runway to …
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
GlobeNewswire
·
April 15, 2025
NORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the EASL …
Extendicare Announces April 2025 Dividend of C$0.042 per Share
GlobeNewswire
·
April 15, 2025
MARKHAM, Ontario, April 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company (the “Common Share”) for the month of April 2025, …
Alberta Cancer Foundation partners with CDL Cancer to advance oncology innovation
GlobeNewswire
·
April 15, 2025
CALGARY, Alberta, April 15, 2025 (GLOBE NEWSWIRE) -- Creative Destruction Lab (CDL) is pleased to announce that the Alberta Cancer Foundation (ACF) is joining the CDL Cancer program. This partnership brings together a shared commitment to accelerate the …
Hydreight Technologies Expands GLP-1 Telehealth Suite with Launch of Liraglutide on VSDHOne Platform
GlobeNewswire
·
April 15, 2025
VANCOUVER, British Columbia and LAS VEGAS, April 15, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight”or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing mobile clinical network and medical platform which enables …
Lisata Therapeutics Announces Research License with Catalent
GlobeNewswire
·
April 15, 2025
BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other …
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
GlobeNewswire
·
April 15, 2025
Precise Volume Measurement Prior to Discharge Identifies Mortality Risk Oak Ridge, TN, April 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced compelling new data …
Avalon GloboCare Partners with SpecialtyHealth, Inc. to Power Police Chiefs’ Fitness Challenge with KetoAir
GlobeNewswire
·
April 15, 2025
FREEHOLD, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced the addition of …
ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
GlobeNewswire
·
April 15, 2025
In combination with atezolizumab or durvalumab Study conducted under the CRADA agreement between NCI and Oryzon MADRID and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage …
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
GlobeNewswire
·
April 15, 2025
HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, …
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
GlobeNewswire
·
April 15, 2025
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living …
Mural Oncology Announces Plans to Explore Strategic Alternatives
GlobeNewswire
·
April 15, 2025
Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans …
FluidForm Bio™ Advances Vascularized Tissue Engineering with New FRESH™ 3D Bioprinting Breakthrough
GlobeNewswire
·
April 15, 2025
WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced a major advancement in vascularized tissue engineering. A newly published study in ACS Biomaterials …
Alignment Healthcare Strengthens Leadership to Scale its AI-Enabled Medicare Advantage Platform with Two Key Appointments
GlobeNewswire
·
April 15, 2025
ORANGE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced pivotal leadership appointments that underscore its dedication to transforming senior health care through technology and exceptional member care. …
Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025
GlobeNewswire
·
April 15, 2025
WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity …
Aspargo Labs CEO to Participate in Panel Discussion at the American Urological Association Innovation Nexus Conference
GlobeNewswire
·
April 15, 2025
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Aspargo Labs, Inc. ("Aspargo Labs" or the "Company"), a Pharmaceutical and MedTech company focused on converting the world's most meaningful medications into liquid oral suspensions for delivery in proprietary …
FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older
GlobeNewswire
·
April 15, 2025
SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U …
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates
GlobeNewswire
·
April 15, 2025
WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported …